Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas

European Journal of Endocrinology

Volumn 151, Issue 6, 2004, Pages 803-809

  Silvestre, Ramona A ^a   Egido, Eva M ^a   Hernández, Raquel ^a   Leprince, Jérome ^b   Chatenet, David ^b   Tollemer, Hélène ^b   Chartrel, Nicolas ^b   Vaudry, Hubert ^b   Marco, José ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CARBACHOL; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PANCREAS EXTRACT; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II [4-11] [3 IODO 6 TYROSINE]; UROTENSIN II [4-11] [8 ALANINE];

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; HORMONE INHIBITION; IMMUNOREACTIVITY; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID; STRUCTURE ACTIVITY RELATION; VASCULAR RING;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; BLOOD GLUCOSE; CALCIUM CHANNEL AGONISTS; CARBACHOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION, CHEMICAL; INSULIN; MALE; PANCREAS; PANCREATIC EXTRACTS; PARASYMPATHOMIMETICS; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; UROTENSINS;

EID: 11844271454     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510803     Document Type: Article

References (50)

1. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS & Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. PNAS 1980 77 5021-5024.
2. Conlon JM. Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research. Regulatory Peptide 2000 93 3-12.
3. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA & Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. PNAS 1998 95 15803-15808.
4. Coulouarn Y, Jegou S, Tostivint H, Vaudry H & Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Letters 1999 457 28-32.
5. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O & Fujino M. Urotensin-II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR(GPR14). Biochemical and Biophysical Research Communications 1999 265 123-129.
6. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J & Aiyar NV. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. British Journal of Pharmacology 2002 136 9-22.
7. Itoh H, McMaster D & Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. European Journal of Pharmacology 1998 149 61-66.
8. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A & Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure activity relationships and nuclear resonance studies on urotensin II. Journal of Medicinal Chemistry 2002 45 1799-1805.
9. Kinney WA, Almond HR Jr, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, Feinstein MA, Leung PA & Maryanoff BE. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angewandte Chemie (International edition in English) 2002 41 2940-2944.
10. Labarrère P, Chatenet D, Leprince J, Marionneau C, Loirand G, Tonon MC, Dubessy C, Scalbert E, Pfeiffer B, Renard P, Calas B, Pacaud P & Vaudry H. Structure-activity relationships of human urotensin II on rat aortic ring contraction. Journal of Enzyme Inhibition and Medicinal Chemistry 2003 18 77-88.
11. Conlon JM, Tostivint H & Vaudry H. Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives. Regulatory Peptide 1997 69 95-103.
12. Coulouarn Y, Fernex C, Jegou S, Henderson CE, Vaudry H & Lihrmann I. Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. Mechanisms of Development 2001 101 187-190.
13. Pelletier G, Lihrmann I & Vaudry H. Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord. Neuroscience 2002 115 525-532.
14. Dun SL, Brailoiu GC, Yang J, Chang JK & Dun NJ. Urotensin-II immunoreactivity in the brainstem and spinal cord of the rat. Neuroscience Letters 2001 305 9-12.
15. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu W-S, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ & Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999 401 282-286.
16. Douglas SA & Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends in Cardiovascular Medicine 2000 10 229-237.
17. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF & Caskey CT. Identification of urotensin-II as the endogenous ligand for the orphan-G-protein-coupled receptor GPR14. Biochemical and Biophysical Research Communications 1999 266 174-178.
18. Nothacker HP, Wang Z, Zhu Y, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP & Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nature Cell Biology 1999 1 383-385.
19. Marchese A, Heiber M, Nguyen T, Heng HHQ, Saldivia VR, Cheng R, Murphy PM, Tsui LC, Shi X, Gregor P, George SR, O'Dowd BF & Docherty JM. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 1995 29 335-344.
20. Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M & Thompson DA. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochemical and Biophysical Research Communications 1995 209 752-759.
21. Nehring RB, Meyerhof W & Richter D. Aspartic acid residue 124 in the third transmembrane domain of the somatostatin receptor subtype 3 is essential for somatostatin-14 binding. DNA and Cell Biology 1995 14 939-944.
22. Strand J & Hadcock JR. Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochemical and Biophysical Research Communications 1995 216 913-921.
23. Chen L, Hoeger C, Rivier J, Fitzpatrick VD, Vandlen RL & Tashjian AH. Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin. Biochemical and Biophysical Research Communications 1999 258 689-694.
24. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H & Murakami O. Role of urotensin II in patient on dialysis. Lancet 2001 358 810-811.
25. Richards AM, Nicholls MG, Lainchbury JG, Fisher S & Yandle TG. Plasma urotensin II in heart failure. Lancet 2002 360 545-546.
26. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P & Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. American Journal of Physiology 2003 284 H1576-H1581.
27. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S & Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clinical Science 2003 104 1-5.
28. Sun HX, Du WN, Zuo J, Wu GD, Shi GB, Shen Y, Qiang BQ, Yao ZJ, Hang JM, Wang H, Huang W Chen Z & Fang FD. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of north China. Zhongguo Yi Xue Ke Xue Yan Xue Bao 2002 24 223-227.
29. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J & Oka Y. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003 56 972-976.
30. Silvestre RA, Rodríguez-Gallardo J, Egido EM & Marco J. Inhibition of insulin release by uroterisin II. A study on the perfused rat pancreas. Hormone and Metabolic Research 2001 33 379-381.
31. Flatt PR. The hormonal and neural control of endocrine pancreatic function. In Textbook of Diabetes, edn 3, ch. 11, pp 11.1-11.21. Eds J-C Pickup & G Williams. Oxford: Blackwell Publishing, 2003.
32. Silvestre RA, Miralles P, Moreno P, Villanueva ML & Marco J. Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat. Biochemical and Biophysical Research Communications 1986 134 1291-1297.
33. Herbert V, Lau KS, Gottlieb CW & Bleicher SJ. Coated charcoal immunoassay of insulin. Journal of Clinical Endocrinilogy and Metabolism 1965 25 1375-1384.
34. Vaudry H, Tonon MC, Delarue C, Vaillant R & Kraicer J. Biological and radioimmunological evidence for melanocyte stimulating hormones (MSH) of extrapituitary origin in the rat brain. Neuroendocrinology 1978 27 9-24.
35. Chartrel N, Leprince J, Dujardin C, Chatenet D, Tollemer H, Baroncini M, Balment RJ, Bauvillain JC & Vaudry H. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. Journal of Neurochemistry (In Press).
36. Carotenuto A, Grieco P, Campiglia P, Novellino E & Rovero P. Unraveling the active conformation of urotensin II. Journal of Medicinal Chemistry 2004 47 1652-1661.
37. Maguire JJ, Kuc RE & Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. British Journal of Pharmacology 2000 131 441-446.
38. Zawalich WS & Zawalich KC. Regulation of insulin secretion by phospholipase C. American Journal of Physiology 1996 271 E409-E416.
39. Gilon P & Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocrine Reviews 2001 22 565-604.
40. Creutzfeldt W & Nauck M. Gut hormone and diabetes mellitus. Diabetes/Metabolism Reviews 1992 8 149-177.
41. Delmeire D, Flamez D, Hinke SA, Cali JJ, Pipeleers D & Schuit F. Type VIII adenyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1. Diabetologia 2003 46 1383-1393.
42. Brown AM, Kunze DL & Yatani A. The agonist effect of dihydropyridines on calcium channels. Nature 1984 311 570-572.
43. Hess P, Lansman JB & Tsien RW. Different modes of Ca channel gating behaviour favoured by dihydropyridine calcium agonists and antagonists. Nature 1984 311 538-544.
44. Gibson A, Bern HA, Ginsburg M & Botting JH. Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle. PNAS 1984 81 625-629.
45. Itoh H, Itoh Y, Rivier J & Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin III American Journal of Physiology 1987 252 R361-R366.
46. Loretz CA & Assad JA. Urotensin II lowers cytoplasmic free calcium concentration in goby enterocytes: measurements using quin2. General and Comparative Endocrinology 1996 64 355-361.
47. Sharp GW. Mechanisms of inhibition of insulin release. American Journal of Physiology 1996 271 C1781-C1799.
48. 2+ concentration. Journal of Biological Chemistry 1989 264 973-980.
49. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe N, Ishibashi Y, Kitada C, Miyakima N, Suzuki N, Mori M & Fujino M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochemical and Biophysical Research Communications 310 860-868.
50. Thompson JP, Watt P, Sanghavi S, Strupish JW & Lambert DG. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesthesia and Analgesia 2003 97 1501-1503.